Lesley S Park1, Janet P Tate, Keith Sigel, David Rimland, Kristina Crothers, Cynthia Gibert, Maria C Rodriguez-Barradas, Matthew Bidwell Goetz, Roger J Bedimo, Sheldon T Brown, Amy C Justice, Robert Dubrow. 1. aStanford University School of Medicine, Stanford, California bVeterans Affairs Connecticut Healthcare System, West Haven cYale School of Medicine, New Haven, Connecticut dIcahn School of Medicine at Mt. Sinai, New York, New York eAtlanta Veterans Affairs Medical Center fEmory University School of Medicine, Atlanta, Georgia gUniversity of Washington School of Medicine, Seattle, Washington hWashington DC Veterans Affairs Medical Center iGeorge Washington University School of Medicine and Health Sciences, Washington, District of Columbia jMichael E. DeBakey Veterans Affairs Medical Center kBaylor College of Medicine, Houston, Texas lVeterans Affairs Greater Los Angeles Healthcare System mDavid Geffen School of Medicine, University of California, Los Angeles, California nVeterans Affairs North Texas Healthcare System oUniversity of Texas Southwestern Medical Center, Dallas, Texas pJames J. Peters Veterans Affairs Medical Center, New York, New York qYale School of Public Health, New Haven, Connecticut, USA.
Abstract
OBJECTIVE: Utilizing the Veterans Aging Cohort Study, the largest HIV cohort in North America, we conducted one of the few comprehensive comparisons of cancer incidence time trends in HIV-infected (HIV+) versus uninfected persons during the antiretroviral therapy (ART) era. DESIGN: Prospective cohort study. METHODS: We followed 44 787 HIV+ and 96 852 demographically matched uninfected persons during 1997-2012. We calculated age-, sex-, and race/ethnicity-standardized incidence rates and incidence rate ratios (IRR, HIV+ versus uninfected) over four calendar periods with incidence rate and IRR period trend P values for cancer groupings and specific cancer types. RESULTS: We observed 3714 incident cancer diagnoses in HIV+ and 5760 in uninfected persons. The HIV+ all-cancer crude incidence rate increased between 1997-2000 and 2009-2012 (P trend = 0.0019). However, after standardization, we observed highly significant HIV+ incidence rate declines for all cancer (25% decline; P trend <0.0001), AIDS-defining cancers (55% decline; P trend <0.0001), nonAIDS-defining cancers (NADC; 15% decline; P trend = 0.0003), and nonvirus-related NADC (20% decline; P trend <0.0001); significant IRR declines for all cancer (from 2.0 to 1.6; P trend <0.0001), AIDS-defining cancers (from 19 to 5.5; P trend <0.0001), and nonvirus-related NADC (from 1.4 to 1.2; P trend = 0.049); and borderline significant IRR declines for NADC (from 1.6 to 1.4; P trend = 0.078) and virus-related NADC (from 4.9 to 3.5; P trend = 0.071). CONCLUSION: Improved HIV care resulting in improved immune function most likely contributed to the HIV+ incidence rate and the IRR declines. Further promotion of early and sustained ART, improved ART regimens, reduction of traditional cancer risk factor (e.g. smoking) prevalence, and evidence-based screening could contribute to future cancer incidence declines among HIV+ persons.
OBJECTIVE: Utilizing the Veterans Aging Cohort Study, the largest HIV cohort in North America, we conducted one of the few comprehensive comparisons of cancer incidence time trends in HIV-infected (HIV+) versus uninfected persons during the antiretroviral therapy (ART) era. DESIGN: Prospective cohort study. METHODS: We followed 44 787 HIV+ and 96 852 demographically matched uninfected persons during 1997-2012. We calculated age-, sex-, and race/ethnicity-standardized incidence rates and incidence rate ratios (IRR, HIV+ versus uninfected) over four calendar periods with incidence rate and IRR period trend P values for cancer groupings and specific cancer types. RESULTS: We observed 3714 incident cancer diagnoses in HIV+ and 5760 in uninfected persons. The HIV+ all-cancer crude incidence rate increased between 1997-2000 and 2009-2012 (P trend = 0.0019). However, after standardization, we observed highly significant HIV+ incidence rate declines for all cancer (25% decline; P trend <0.0001), AIDS-defining cancers (55% decline; P trend <0.0001), nonAIDS-defining cancers (NADC; 15% decline; P trend = 0.0003), and nonvirus-related NADC (20% decline; P trend <0.0001); significant IRR declines for all cancer (from 2.0 to 1.6; P trend <0.0001), AIDS-defining cancers (from 19 to 5.5; P trend <0.0001), and nonvirus-related NADC (from 1.4 to 1.2; P trend = 0.049); and borderline significant IRR declines for NADC (from 1.6 to 1.4; P trend = 0.078) and virus-related NADC (from 4.9 to 3.5; P trend = 0.071). CONCLUSION: Improved HIV care resulting in improved immune function most likely contributed to the HIV+ incidence rate and the IRR declines. Further promotion of early and sustained ART, improved ART regimens, reduction of traditional cancer risk factor (e.g. smoking) prevalence, and evidence-based screening could contribute to future cancer incidence declines among HIV+ persons.
Authors: Leah L Zullig; George L Jackson; Raye Anne Dorn; Dawn T Provenzale; Rebecca McNeil; Catherine M Thomas; Michael J Kelley Journal: Mil Med Date: 2012-06 Impact factor: 1.437
Authors: Timothy Wilkin; Jeannette Y Lee; Shelly Y Lensing; Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Naomi Jay; David Aboulafia; David L Cohn; Mark H Einstein; Alfred Saah; Ronald T Mitsuyasu; Joel M Palefsky Journal: J Infect Dis Date: 2010-10-15 Impact factor: 5.226
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: Meredith S Shiels; Jessica Y Islam; Philip S Rosenberg; H Irene Hall; Evin Jacobson; Eric A Engels Journal: Ann Intern Med Date: 2018-05-08 Impact factor: 25.391
Authors: Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Wendy Leyden; Romain S Neugebauer; Keri N Althoff; Nancy A Hessol; Chad J Achenbach; John T Brooks; M John Gill; Surbhi Grover; Michael A Horberg; Jun Li; W Christopher Mathews; Angel M Mayor; Pragna Patel; Charles S Rabkin; Anita Rachlis; Amy C Justice; Richard D Moore; Eric A Engels; Michael J Silverberg; Robert Dubrow Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: Robert Dubrow; Li Qin; Haiqun Lin; Raúl U Hernández-Ramírez; Romain S Neugebauer; Wendy Leyden; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Sharada P Modur; Gypsyamber DʼSouza; Ronald J Bosch; Surbhi Grover; Michael A Horberg; Mari M Kitahata; Angel M Mayor; Richard M Novak; Charles S Rabkin; Timothy R Sterling; James J Goedert; Amy C Justice; Eric A Engels; Richard D Moore; Michael J Silverberg Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: Elizabeth L Yanik; Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Wendy Leyden; Romain S Neugebauer; Michael A Horberg; Richard D Moore; W Christopher Mathews; Amy C Justice; Nancy A Hessol; Angel M Mayor; M John Gill; John T Brooks; Jing Sun; Keri N Althoff; Eric A Engels; Michael J Silverberg; Robert Dubrow Journal: J Acquir Immune Defic Syndr Date: 2018-08-15 Impact factor: 3.731
Authors: Lesley S Park; Janet P Tate; Keith Sigel; Sheldon T Brown; Kristina Crothers; Cynthia Gibert; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Roger J Bedimo; Amy C Justice; Robert Dubrow Journal: Ann Intern Med Date: 2018-06-12 Impact factor: 25.391